Sharash相关文献与解析，生知库 | 链接生命科学的每一步

日期影响因子

Impact of chronic fibrosing interstitial lung disease on healthcare use: association between fvc decline and inpatient hospitalization

慢性纤维化间质性肺病对医疗保健利用的影响：FVC下降与住院治疗之间的关联

期刊:BMC Pulmonary Medicine

影响因子:2.8

doi:10.1186/s12890-023-02637-8

Singer, David; Chastek, Benjamin; Sargent, Andrew; Johnson, Jonathan C; Shetty, Sharash; Conoscenti, Craig; Bernstein, Elana J

特发性肺纤维化

发表日期：2023

文献求助收藏

Cost-effectiveness of second-line empagliflozin versus liraglutide for type 2 diabetes in the United States

在美国，二线药物恩格列净与利拉鲁肽治疗2型糖尿病的成本效益分析

期刊:Diabetes Obesity & Metabolism

影响因子:5.7

doi:10.1111/dom.14625

Reifsnider, Odette S; Pimple, Pratik; Brand, Sarah; Bergrath Washington, Evelien; Shetty, Sharash; Desai, Nihar R

发表日期：2022

文献求助收藏

Claims-based Prevalence of Disease Progression among Patients with Fibrosing Interstitial Lung Disease Other than Idiopathic Pulmonary Fibrosis in the United States

美国除特发性肺纤维化以外的纤维化间质性肺疾病患者疾病进展的基于索赔数据的患病率

期刊:Annals of the American Thoracic Society

影响因子:5.4

doi:10.1513/AnnalsATS.202102-222OC

Singer, David; Bengtson, Lindsay G S; Conoscenti, Craig S; Laouri, Marianne; Shetty, Sharash S; Anderson, Amy J; Brown, Kevin K

特发性肺纤维化

发表日期：2022

文献求助收藏

Healthcare Costs and Resource Utilization Associated with the Use of Empagliflozin Versus Other Antihyperglycemic Agents Among Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease: A Real-World Retrospective Cohort Analysis

恩格列净与其他降糖药在2型糖尿病合并心血管疾病患者中的应用及其相关的医疗成本和资源利用情况：一项真实世界回顾性队列分析

期刊:Diabetes Therapy

影响因子:2.6

doi:10.1007/s13300-021-01173-0

Raju, Aditya; Pimple, Pratik; Stafkey-Mailey, Dana; Farrelly, Eileen; Shetty, Sharash

心血管疾病

发表日期：2022

文献求助收藏

Burden of illness in progressive fibrosing interstitial lung disease

进行性纤维化间质性肺疾病的疾病负担

doi:10.18553/jmcp.2022.28.8.871

Singer, David; Bengtson, Lindsay G S; Conoscenti, Craig S; Anderson, Amy J; Brekke, Lee; Shetty, Sharash S; Brown, Kevin K

发表日期：2022

文献求助收藏

Cost-effectiveness analysis of empagliflozin versus sitagliptin as second-line therapy for treatment in patients with type 2 diabetes in the United States

美国2型糖尿病患者二线治疗中，恩格列净与西格列汀的成本效益分析

期刊:Diabetes Obesity & Metabolism

影响因子:5.7

doi:10.1111/dom.14268

Reifsnider, Odette; Kansal, Anuraag; Pimple, Pratik; Aponte-Ribero, Valerie; Brand, Sarah; Shetty, Sharash

发表日期：2021

文献求助收藏

Adoption of Antifibrotic Medications: A Closer Look at the Data

抗纤维化药物的应用：数据深入分析

期刊:Annals of the American Thoracic Society

影响因子:5.4

doi:10.1513/AnnalsATS.202103-359LE

White, Eric S; Nili, Mona; Shetty, Sharash; Leonard, Thomas B

发表日期：2021

文献求助收藏

Hypoglycemia Incidence Rates and Associated Health Care Costs in Patients with Type 2 Diabetes Mellitus Treated with Second-Line Linagliptin or Sulfonylurea After Metformin Monotherapy

二甲双胍单药治疗后接受二线利格列汀或磺脲类药物治疗的2型糖尿病患者的低血糖发生率及相关医疗保健费用

doi:10.18553/jmcp.2016.22.5.483

Raju, Aditya; Shetty, Sharash; Cai, Beilei; D'Souza, Anna O

发表日期：2016

文献求助收藏